All In Biotech

Drug Trial Radar · NCT01262677

Once-A-Day Pregabalin For Partial Seizures

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures

Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

325

Actual

Start

Feb 17, 2011

Primary completion

Jul 31, 2012

Study completion Aug 1, 2012

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.

Conditions

  • Partial Seizures
  • Epilepsies, Partial

Interventions

  • pregabalinDrug

    Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days

  • pregabalinDrug

    Controlled Release Tablets, 165 mg, once per day (QD) for 11 days

  • pregabalinDrug

    Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)

  • pregabalinDrug

    Controlled Release Tablets, 165 mg, once per day (QD) for 7 days

  • pregabalinDrug

    Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days

  • pregabalinDrug

    Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)

  • placeboDrug

    matched to the active drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment PhaseTime frame: Week 0 to Week 14

Locations

82 sites in 18 countries. Site status is shown where the registry gives one.

  • Neurology Clinic, PC

    Northport, Alabama

  • NEA Baptist Clinic

    Jonesboro, Arkansas

  • Clinical Trials, Inc.

    Little Rock, Arkansas

  • Collaborative Neuroscience Network, Inc.

    Long Beach, California

  • Viking Clinic Research Center

    Murrieta, California

  • Viking Clinical Research Center

    Murrieta, California

  • Neurological Research Institute

    Santa Monica, California

  • Viking Clinical Research Center

    Temecula, California

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Optima Neurological Services, LLC

    Gainesville, Florida

  • Sleep Disorders Center of Georgia - Gainesville

    Gainesville, Georgia

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • VCMA Comprehensive Epilepsy Center

    Wichita, Kansas

  • Via Christi Research

    Wichita, Kansas

  • Associates in Neurology, PSC

    Lexington, Kentucky

  • Mid Atlantic Headache Institute

    Pikesville, Maryland

  • Asheville Neurology Specialists, PA

    Asheville, North Carolina

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Mark A. Fisher, M.D.- Private Practice

    Oklahoma City, Oklahoma

  • Sooner Clinical Research

    Oklahoma City, Oklahoma

  • Veroniqe Sebastian, MD

    Oklahoma City, Oklahoma

  • Angelique Barreto, MD

    Oklahoma City, Oklahoma

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • FutureSearch Trials of Neurology

    Austin, Texas

  • Scott and White Healthcare-Office of Sponsored Research Administration

    Temple, Texas

  • Scott & White Healthcare

    Temple, Texas

  • Fundacion Argentina Contra las Enfermedades Neurologicas (FACENE)

    Buenos Aires, Argentina

  • Clinic of Neurology,Clinical Centar University Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • MBAL Puls AD, Nevrologichno otdelenie

    Blagoevgrad, Bulgaria

  • UMBAL Dr. Georgi Stranski, Vtora nevrologichna klinika

    Pleven, Bulgaria

  • DKTs Akta Medika, Konsultativen kabinet po Nevrologiya

    Sevlievo, Bulgaria

  • MBALNP Sveti Naum EAD, Klinika po nervni bolesti za paroksizmalnite sastoyaniya,

    Sofia, Bulgaria

  • Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie, Nevrologichno Otdelenie

    Sofia, Bulgaria

  • Litomyslská nemocnice, a.s.

    Litomyšl, Czechia

  • Fakultni Thomayerova nemocnice s poliklinikou,Neurologicka klinika IPVZ/FTNsP

    Prague, Czechia

  • Neurologicka ambulance

    Prague, Czechia

  • Epilepsie-Zentrum Bethel

    Bielefeld, Germany

  • Praxis fuer Neurologie und Psychiatrie, Psychotherapie

    Bielefeld, Germany

  • Klinik fuer Epileptologie, Universitaet Bonn

    Bonn, Germany

  • Neuro Consil GmbH

    Düsseldorf, Germany

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.